MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
PerkinElmer Total Assets 2011-2026 | PKI
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets PerkinElmer
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.2 B | 12.4 B | 13.6 B | 15 B | 7.96 B | - | 6.54 B | 5.98 B | 4.28 B | 4.17 B | - | 4.13 B | 3.95 B | 3.83 B | 3.21 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 15 B | 3.21 B | 7.47 B |
Quarterly Total Assets PerkinElmer
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.1 B | 12.4 B | 12.4 B | 12.4 B | 12.8 B | 13.4 B | 13.4 B | 13.6 B | 13.4 B | 14.2 B | 14.6 B | 14.1 B | 13.8 B | 14.2 B | 14.8 B | 7.96 B | 14.9 B | 8.74 B | 8.76 B | - | 6.87 B | 6.64 B | 6.38 B | 6.54 B | 6.54 B | 6.54 B | 6.54 B | 5.98 B | 5.98 B | 5.98 B | 5.98 B | 6.09 B | 6.09 B | 6.09 B | 6.09 B | 4.17 B | 4.3 B | 4.19 B | 4.21 B | - | 4.03 B | 4.08 B | 4.03 B | 4.13 B | 4.13 B | 4.13 B | 4.13 B | 3.95 B | 3.95 B | 3.95 B | 3.95 B | 3.9 B | 3.9 B | 3.9 B | 3.9 B | 3.21 B | 3.4 B | 3.6 B | 3.31 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.9 B | 3.21 B | 7.49 B |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
10.7 B | $ 114.87 | -0.65 % | $ 34.9 B |  USA |
 |
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | USA |
 |
Aspira Women's Health
AWH
|
5.46 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
377 K | - | - | $ 9.42 M |  Israel |
 |
Co-Diagnostics
CODX
|
24.7 M | $ 1.63 | -1.21 % | $ 2.17 M | USA |
 |
Castle Biosciences
CSTL
|
531 M | $ 24.7 | -1.12 % | $ 686 M | USA |
 |
CareDx, Inc
CDNA
|
413 M | $ 21.91 | 0.27 % | $ 1.17 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M |  Britain |
 |
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
5.86 B | - | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
1.22 B | $ 15.3 | -1.92 % | $ 463 M | USA |
 |
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
7.14 B | $ 166.79 | -2.59 % | $ 8.27 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Guardant Health
GH
|
2.01 B | $ 83.09 | -6.11 % | $ 10.4 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
26.9 B | $ 27.12 | -1.53 % | $ 20 B |  Niderland |
 |
Illumina
ILMN
|
6.3 B | $ 126.92 | -1.24 % | $ 20.2 B | USA |
 |
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | USA |
 |
Interpace Biosciences
IDXG
|
33.8 M | $ 1.93 | - | $ 8.54 M | USA |
 |
Lantheus Holdings
LNTH
|
2.23 B | $ 83.55 | -0.67 % | $ 5.64 B | USA |
 |
QIAGEN N.V.
QGEN
|
6.28 B | - | - | $ 10.6 B | Niderland |
 |
Medpace Holdings
MEDP
|
1.98 B | $ 409.65 | -2.78 % | $ 11.8 B | USA |
 |
Biomerica
BMRA
|
5.94 M | $ 2.19 | 0.46 % | $ 5.03 M | USA |
 |
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | Israel |
 |
ICON Public Limited Company
ICLR
|
16.9 B | $ 102.49 | -0.7 % | $ 8.45 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 259.57 | -1.47 % | $ 21.6 B | USA |
 |
NeoGenomics
NEO
|
1.36 B | $ 9.02 | 4.76 % | $ 1.16 B | USA |
 |
Celcuity
CELC
|
467 M | $ 120.07 | -4.46 % | $ 5.61 B | USA |
 |
Neogen Corporation
NEOG
|
3.44 B | $ 9.34 | -1.16 % | $ 2.03 B | USA |
 |
National Research Corporation
NRC
|
135 M | $ 16.84 | -1.58 % | $ 377 M | USA |
 |
Myriad Genetics
MYGN
|
707 M | $ 4.84 | 0.21 % | $ 448 M | USA |
 |
Natera
NTRA
|
1.39 B | $ 200.17 | -2.06 % | $ 19.7 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 195.05 | -0.8 % | $ 21.7 B | USA |
 |
Invitae Corporation
NVTA
|
1.95 B | - | - | $ 21.2 M | USA |
 |
OpGen
OPGN
|
9.86 M | - | -16.95 % | $ 1.54 M | USA |
 |
Organovo Holdings
ONVO
|
14.6 M | - | -2.3 % | $ 19.4 M | USA |
 |
Precipio
PRPO
|
21.3 M | $ 31.75 | 3.42 % | $ 51 M | USA |
 |
Personalis
PSNL
|
270 M | $ 5.5 | -7.72 % | $ 326 M | USA |
 |
Senseonics Holdings
SENS
|
126 M | $ 7.18 | -1.24 % | $ 300 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
2.28 B | $ 16.65 | -12.64 % | $ 179 M | China |